Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism

<div><sup>31</sup>P-NMR spectra acquired from chemical extracts (aqueous) prepared from untreated LNCaP cells (a) or LNCaP cells treated for 48 h with paclitaxel (5 nM) (b), Epi-1 (40 <i>μ</i>M) (c), or flutamide (20 <i>μ</i>M) (d). (1APPA: standard; PE: phosphoethanolamine; PC: phosphocholine; Pi: inorganic phosphate; GPE: glycerophosphorylethanolamine; GPC: glycerophosphorylcholine; NTP: nucleoside triphosphates; NAD: nucleotide adenine dinucleotide; DPDE: diphosphodiester sugars).</div>

BioMed Research International

fig4

Figure 4

Figure 4: Response Detection of Castrate-Resistant Prostate Cancer to Clinically Utilised and Novel Treatments by Monitoring Phospholipid Metabolism 